Show simple item record

dc.contributor.authorEvans-Lacko, Sara
dc.contributor.authorKoeser, Leonardo
dc.contributor.authorKnapp, Martin
dc.contributor.authorLonghitano, Calogero
dc.contributor.authorZohar, Joseph
dc.contributor.authorKuhn, Karl
dc.date.accessioned2019-03-22T06:32:32Z
dc.date.available2019-03-22T06:32:32Z
dc.date.issued2016
dc.identifier.issn0924-977X
dc.identifier.doi10.1016/j.euroneuro.2016.03.005
dc.identifier.urihttp://hdl.handle.net/10072/99968
dc.description.abstractDepression is the most common psychiatric illness and cause of disability, and associated with durable impacts on productivity and represents one of the major causes of workplace absenteeism and presenteeism. Few studies, however, examine the economic impact of treatment of depression in the workplace, particularly from the perspective of the employer. We estimated the relative cost-effectiveness of treatment for employees with depression in the workplace. We used a decision-analytic model to estimate the relative cost-effectiveness of (i) psychotherapy, (ii) pharmacotherapy and (iii) combination of psychotherapy and pharmacotherapy and whether they reduce sickness, absenteeism and presenteeism for people with depression. Costs and savings to the employer were also estimated, and policy recommendations made about how best to translate this evidence into practice. Both pharmacotherapy treatment and psychotherapy treatment were found to be cost-saving from the perspective of the employer. Psychotherapy was found to be the most cost-effective option with an incremental cost-effectiveness ratio of €22,225. This study provides evidence that screening and treatment for depression in the workplace is cost-effective and represents a worthwhile investment from the business perspective.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherElsevier
dc.relation.ispartofpagefrom1004
dc.relation.ispartofpageto1013
dc.relation.ispartofjournalEuropean Neuropsychopharmacology
dc.relation.ispartofvolume26
dc.subject.fieldofresearchPsychology and Cognitive Sciences not elsewhere classified
dc.subject.fieldofresearchMedical and Health Sciences
dc.subject.fieldofresearchPsychology and Cognitive Sciences
dc.subject.fieldofresearchcode179999
dc.subject.fieldofresearchcode11
dc.subject.fieldofresearchcode17
dc.subject.keywordsDepression
dc.subject.keywordsEmployment
dc.subject.keywordsCost-effectiveness
dc.subject.keywordsEconomic evaluation
dc.subject.keywordsMental illness
dc.titleEvaluating the economic impact of screening and treatment for depression in the workplace
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorKuhn, Karl


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record